CD1C and neoplasm: Among APC-based anticancer vaccines, DC-based anticancer vaccines—either created with primary CD1c+ myeloid DCs or engineered by fusion with patient-derived tumor cells, pulsation with tumor peptides/lysate, or electroporation with tumor associated antigen-encoding mRNA—have elucidated promising immunologic and/or clinical responses in B-cell lymphoma (296), multiple myeloma (297), acute myeloid leukemia (298), glioblastoma (299), and metastatic melanoma (300–302).